Q-omics provides the consensus-scored RPL31P63 profile across patient tissues and cancer cell-line models. RPL31P63 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL31P63 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RPL31P63 RNA expression shows 12,206 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where RPL31P63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL31P63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL31P63 survival associations across molecular data types. RPL31P63 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL31P63 RNA expression–survival associations across cancer types. High RPL31P63 expression shows unfavorable associations in ACC, KIRP, STAD and SARC, but favorable associations in LUSC and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL31P63 RNA expression.
This table summarizes RPL31P63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL31P63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL31P63 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, KIRP, PRAD and CHOL. The KIRC box plot shows higher RPL31P63 RNA expression in tumor versus normal tissue (log2 FC = +0.350, t-test p < 0.001).
This table shows molecular features associated with RPL31P63 in patient tissues and cancer cell lines. In patient samples, RPL31P63 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
